5Kipp B R,Karnes R J,Brankley S M,et al.Monitoring int ravesical therapy for superficial bladder cancer using fluorescence in situ hybridization[].Journal d Urologie.2005
6Kruger S,Mess F,Bohle A,et al.Numerical aberrations of chromosome 17 and 9p21 locus are independent predictors of number recurrence in no invase transitional cell carcinoma of urinary bladder[].International Journal of Oncology.2003
7.invase transitional cell carcinoma of urinary bladder[].International Journal of Oncology.2003
8Simon R,Burger H,Brinkschmidt C,Bocker W,et al.Chromosomal aber2rations associated with invasion in papillary superficial bladder cancer[].Journal of Paleopathology.1998
9Chaturvedi V,Li L,Hodgeo S,et al.Superimposed hitologic and genetic mapping of charomosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the Bladder[].Journal of National Cancer Institute.1995
10Qureshi K N,Lunec J,Neal D E,et al.Molecular biological changes in bladder cancer[].Cancer Surveys.1998
3Kipp BR, Karnes RJ, Brankley SM, et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence insitu hybridization[J]. J Urol,2005,173:401.
4Gallucci M, Guadagni F, Marzano R, et al. Status of the p53, p16, RB1, and HER-2 genes and chromosomes 3, 7,9, and 17 in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters[J]. J Clin Pathol, 2005,58(4) : 367-371.
5Kruger S, Mess F, Bohle A, et al. Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder[J]. Int J Oncol,2003,23(1) :41-48.
6Mhawech-Fauceglia P, Fischer G, Beck A, et al. Raf1,Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma: a retrospective TMA study of 246 patients with long-term follow-up [J]. Eur J Surg Oncol,2006,32(4) :439-444.
7Bartlett JMS, Adie L, Watters AD, et al. Chromosome aberrations in transitional cell carcinoma that predictive of disease outcome are independent of polyploidy. BJU International, 1999 ,84: 775 - 779.
8Bartlett JMS, Watters AD, Ballantyne SA, et al. Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder?. Br J Cancer, 1998,77(12) :2193 - 2198.
9Edwards J, Duncan P, Going JJ, et al. Identification of loci associated with putative recurrence gene in transitional cell carcinoma of the urinary bladder. J Pathol, 2002,196: 380 - 385.
10Miyao N, Tsai YC, Lerner SP, et al. Role of chromosome 9 in human bladder cancer. Cancer Res, 1993,53:4066- 4070.
1Capitanio U,Isbarn H, Shariat S F,et al. Partial cys-tectomy does not undermine cancer control in appropri-ately selected patients with urothelial carcinoma of thebladder: a population-based matched analysist[J], U-rology,2009,74: 858 — 864.
2Kassouf W,Swanson D, Kamat A M,et al. Partialcystcctomy for muscle invasive urothelial carcinoma ofthe bladder: a contemporary review of the M. D. An-derson Cancer Center experience [J]. J Urol, 2006,175 : 2058 一 2062.
3Efstathiou J A, Spiegel I) Y,Shipley W U, et al.Long-term outcomes of selective bladder preservationby combined-modality therapy for invasive bladdercancer: the MGH experience[J]. Eur Urol, 2012 , 61:705 — 711.
4Prout GR Jr, Barton BA, Griffin PP, et al. Treated history of noninvasive grade 1 transitional cell carcinoma. The National Blad- der Cancer Group[J]. J Urol, 1992,148 (5) : 1413-1419.
5Lotan Y, Bensalah K, Ruddell T, et al. Prospective evalua tion of the clinical usefulness of reflex fluorescence in situ hy bridization assay in patients with atypical cytology for the de tection of urothelial carcinoma of the bladder[J]. J Urol 2008,179(6), 2164-2169.
6Michael F, Sarosdy MF, Schellhammer P, et al. Clinical e- valuation of a Multi-target fluorescent in situ hybridization assay for detection of bladder cancer[J]. J UroI, 2002, 168 (5) : 1950-1954.
